Preferred Label : relugolix;

MeSH note : structure in first source;

CISMeF synonym : TAK 385; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)pyrimidin-6-yl)phenyl)-3-methoxyurea;

MeSH hyponym : TAK385; TAK-385;

Is substance : O;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3530112/fr/ryeqo-relugolix/estradiol/acetate-de-norethisterone-endometriose
2024
false
false
false
France
administration, oral
drug combinations
treatment outcome
insurance, health, reimbursement
estradiol
relugolix
relugolix, estradiol and norethisterone
evaluation of the transparency committee
endometriosis
Norethindrone Acetate

---
https://www.has-sante.fr/jcms/p_3554612/fr/ryeqo-relugolix/estradiol/acetate-de-norethisterone-endometriose-fibromes-uterins
2024
false
false
false
France
drug combinations
treatment outcome
insurance, health, reimbursement
relugolix
relugolix, estradiol and norethisterone
estradiol
administration, oral
fibroid uterus
evaluation of the transparency committee
leiomyoma
endometriosis
Norethindrone Acetate

---
https://www.has-sante.fr/jcms/p_3434157/fr/orgovyx-relugolix-cancer-de-la-prostate-avance-hormonodependant
2023
false
false
false
France
orgovyx
neoplasms, hormone-dependent
treatment outcome
insurance, health, reimbursement
advanced hormone-dependent prostate cancer
adult
Product containing precisely relugolix 120 milligram/1 each conventional release oral tablet (clinical drug)
administration, oral
relugolix
androgen antagonists
evaluation of the transparency committee
relugolix
prostatic neoplasms

---
https://www.ema.europa.eu/en/medicines/human/EPAR/ryeqo
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
relugolix
relugolix
drug approval
europe
endometriosis
estradiol
estradiol
relugolix, estradiol and norethisterone
Norethindrone Acetate
Norethindrone Acetate
fibroid uterus
administration, oral
risk management
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical

---
Nous contacter.
03/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.